Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia
Authors:
- 14 March 2007
- journal article
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 61 (2) , 174-180
Abstract
Abstract Previous reports have shown that both A1 allele carriers of TaqI A and Del allele non‐carriers of −141C Ins/Del for dopamine D2 receptor (DRD2) gene polymorphisms have a better antipsychotic drug response. The present study aimed to examine the validity of a combination of these two DRD2 polymorphisms as predictors for response to DRD2 antagonists. The subjects consisted of 49 acutely exacerbated inpatients with schizophrenia treated with bromperidol (30 cases, 6–18 mg/day) or nemonapride (19 cases, 18 mg/day) for 3 weeks. Brief Psychiatric Rating Scale and Udvalg for Kliniske Undersøgelser side‐effects rating scale were used for clinical assessments. DRD2 genotypes were determined using a polymerase chain reaction method. In the overall 49 subjects, combined DRD2 polymorphisms weakly predicted the response to DRD2 antagonists (Fisher exact test, P = 0.049), that is, good response in A1(+) or Del(–) subjects and poor response in A1(–) plus Del(+) subjects. In the former subjects, non‐responders with A1(+) or Del(–) showed higher scores of psychic, extrapyramidal and total side‐effects. At therapeutic doses (6–8 mg/day haloperidol equivalent dose) in 30 subjects, the predictability of response was greatly increased (Fisher exact test, P < 0.0045) with higher positive and negative predictive values (78.3% and 85.7%, respectively). These findings suggest that combined DRD2 polymorphisms can be used as a pretreatment marker for response to DRD2 antagonists at therapeutic doses, and that A1(+) or Del(–) subjects are highly sensitive to DRD2 antagonists, expressed as either treatment responders or non‐responders vulnerable to extrapyramidal symptoms.Keywords
This publication has 25 references indexed in Scilit:
- Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patientsNeuroscience Letters, 2005
- The Effects of Olanzapine on the 5 Dimensions of Schizophrenia Derived by Factor AnalysisThe Journal of Clinical Psychiatry, 2001
- Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteersMolecular Psychiatry, 1999
- The D2 Dopamine Receptor GeneAlcohol, 1998
- The Relationship Between Serum Concentration and Therapeutic Effect of Haloperidol in Patients with Acute SchizophreniaClinical Pharmacokinetics, 1998
- D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allelePharmacogenetics, 1997
- A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophreniaHuman Molecular Genetics, 1997
- Haloperidol plasma levels and clinical response: a therapeutic window relationshipAmerican Journal of Psychiatry, 1992
- Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine D-2 receptor binding to rat striatumEuropean Journal of Pharmacology, 1989
- Determination of bromperidol in serum by automated column-switching high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1989